Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

YM BioSciences USA Inc.

Division of Gilead Sciences Inc.
www.ymbiosciences.com

Latest From YM BioSciences USA Inc.

Amdipharm: From Pharmacist to Pharma Firm

Amdipharm was set up in April 2003 to find and market niche products in areas of real clinical need, considered too small-or unsexy-for larger players. Wholly-owned by UK-based distributor and wholesaler Waymade Healthcare, which started out as a chain of pharmacies, Amdipharm's management reckons that the group's experience across the drug distribution chain, particularly at the buyer's end, and its proven deal making prowess, will help it achieve its aim of becoming a successful European pharma company.
BioPharmaceutical Europe

Biotech's Euro-Marketing Gambit

Europe presents a big opportunity--but also significant challenges--to niche players seeking to expand. Some firms--such as US group Cephalon--have bought big in Europe, others like Shire and Celltech have made do with smaller acquisitions onto which they hope to build their own tailored infrastructure. No single approach is the same, and none has yet proven a clear winner. But all depend on finding the right products.
BioPharmaceutical Strategy

Innovation Without Discovery

What's the fastest, lowest-risk route to an approved drug? Develop somebody else's clinical-stage therapeutic. But finding them is tough--and to get a reasonable return on investment, the in-licensor needs to bring value the originator couldn't.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Alias(es)
  • Zarix Inc.
  • Eximias Pharmaceutical Corp.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Gilead Sciences Inc.
  • Senior Management
  • Nick Glover, CEO
    Len Vernon, VP, Fin. & Admin.
    Ernest Wong, PhD, VP, Bus. Dev.
  • Contact Info
  • YM BioSciences USA Inc.
    Phone: (610) 560-0600
    701 Lee Rd.
    Ste. 200
    Wayne, PA 19087
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register